Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

News: Novel Concepts Medical announces groundbreaking results for first plant-based COVID-19 treatment

publication date: Jan 7, 2022
 | 
author/source: Novel Concepts Medical

news-novel-concepts-medical-announces-groundbreaking 

Groundbreaking Medicine Successfully Disrupted COVID-19 Spike Protein Attachment into Host Cells, Intended to Stop Omicron

Novel Concepts Medical, founded by Rachel Alkalay, PhD, and based in Tel Aviv, is delighted to announce the successful testing of its plant-based formulations for the treatment of SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

The testing methodology was devised by Dr. Alkalay, who is the inventor of these formulations.

The testing, led by Tracey Campbell, PhD, was carried out by the Centre for Microbial Chemical Biology at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University in Ontario, Canada.

The first test demonstrated the ability to disrupt the SARS-CoV-2 spike-ACE2 receptor interaction, which is a therapeutic target for COVID-19. Disruption of this interaction will prevent viral entry into cells.

The second test demonstrated the ability to disrupt the TMPRSS2, which represents an additional therapeutic target for COVID-19.

The third test demonstrated anti-viral activity in cell culture.

The testing program concluded: "The NCM formulations act on multiple targets required for SARS CoV-2 infection. This has been demonstrated by in vitro enzyme testing and cell culture assays with a surrogate human coronavirus. This data suggests that these formulations are potential candidates for treatment of SARS CoV-2 infections."

Dr. Alkalay said that her invention is unique because it is the first in the world to decompose the attachment of sugar residues to proteins in the SARS-CoV-2 spike glycoproteins, which play essential roles in the virus attachment, fusion, and entry into the host cells. Therefore, it may very potentially STOP OMICRON and other mutations.

The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours. Specifically, all volunteers with positive PCR tests had negative PCR tests within 48 hours of taking NCM’s formulations, with no side effects. These case studies also demonstrated significant improvement of numerous Long COVID-19 symptoms, including fatigue, headaches, loss of taste and smell, fever, throat ache, and memory loss.

Earlier pre-clinical studies, which were published in January 2021, showed the company has successfully decreased the spike protein in just six hours.

 

learn more

 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners